Fig. 2: HOXB3 promotes CRPC resistance to abiraterone in vitro and in vivo, see also Fig. S1.

A, D Cell growth in the presence of different concentrations of abiraterone actate was measured in LA-Control/LA-HOXB3 and C4-2-Control/C4-2-HOXB3. IC50 values are indicated by dotted lines. B, E MTT assays were performed in LA-Control/LA-HOXB3 or C4-2-Control/C4-2-HOXB3 cells after treated with DMSO or 10 μmol/L abiraterone (Abi) for indicated time. C, F LA-Control/LA-HOXB3 or C4-2-Control/C4-2-HOXB3 cells were treated with DMSO or 10 μmol/L Abi in charcoal stripped serum for 96 h. Fifty million cells were collected from each group followed by testosterone level examination by LC-MS, and the supernatants were subjected to PSA value test by ELISA. G, H qRT-PCR assays were performed in LA-Control/LA-HOXB3 or C4-2-Control/C4-2-HOXB3 cells after treated with DMSO or 10 μmol/L abiraterone (Abi) for 96 h. I LA-Control or LA-HOXB3 cells were injected subcutaneously in mice and grown until tumors reached a size of ~100 mm³. Xenografted mice were then randomly treated with vehicle control or abiraterone acetate (200 mg/Kg, p.o). Caliper measurements were taken weekly. n = 8 mice per group. J Scatter plots with bar showing individual tumor volumes at 28 days post-randomization in each group (n = 8 per group). K Bar graph showing HOXB3 stable suppression in indicated tumors at 28 days post-randomization. HOXB3 mRNA levels were measured by qRT-PCR. Error bars indicate mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.